BMP2 and neoplasm: These collective findings underscore the need to elucidate BMP-dependent mechanisms within the tumor microenvironment, characterize subtype-specific signaling outcomes (particularly for BMP-2/4/7), and determine whether Noggin’s therapeutic potential derives from selective inhibition of specific BMP isoforms.